The thesis

Geron Corporation is a biopharmaceutical company developing treatments for myeloid blood cancers. Its revenue growth is 30.9% year-over-year, but its net margin is -3548.0%, indicating significant financial losses. The analyst consensus rating is BUY, despite a conviction score of 45/100, suggesting moderate confidence. This discrepancy makes the company's setup interesting,

Why now

The current macro context, with the US-China squeeze and Middle East war, may impact the company's valuation. Geron's DCF intrinsic value of $-8 suggests a potential undervaluation, making it a crucial moment to assess the company's prospects.

What to watch

The outcome of imetelstat's Phase 3 clinical trial will be a key indicator of the company's future prospects. Investors should also monitor Geron's revenue growth and net margin over the next few quarters to assess the company's ability to achieve profitability.

Key risks

The company's significant financial losses, with a net margin of -3548.0%, pose a substantial valuation risk. Execution risk is also a concern, as Geron's primary drug candidate, imetelstat, is still undergoing Phase 3 clinical evaluation. Additionally, the company's gross margin of 8659.0% may not be sustainable,

Upcoming catalysts